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ABSTRACT 
Objective: Functional dyspepsia (FD) is a chronic gastroduodenal disorder. Individuals with 
FD demonstrate visceral hypersensitivity, abnormal central pain processing, and low mood, 
but it is unclear whether psychotropic drugs are an effective treatment for the condition. We 
performed a systematic review and meta-analysis of randomised controlled trials (RCTs). 
Design: MEDLINE, EMBASE, EMBASE Classic, PsychINFO, and the Cochrane Controlled 
Trials Register were searched (up to June 2015) for RCTs recruiting adults with FD 
comparing psychotropic drugs with placebo. We contacted authors directly to maximise trial 
eligibility and minimise risk of bias for studies. Dichotomous symptom data were pooled to 
obtain relative risk (RR) of remaining symptomatic after therapy, with 95% confidence 
intervals (CI).  
Results: The search identified 2795 citations; 13 RCTs (1241 patients) were eligible. Ten 
trials were low risk of bias. The RR of FD symptoms not improving with psychotropic drugs 
versus placebo was 0.78 (95% CI 0.68-0.91) (number needed to treat = 6; 95% CI 4-16). 
However, benefit was limited to antipsychotics and tricyclic antidepressants. When only 
studies that excluded individuals with co-existent mood disorder were considered, there was 
no benefit. Total numbers of adverse events and adverse events leading to withdrawal were 
significantly more common, with a number needed to harm of 21 for both.  
Conclusion: Psychotropic drugs may be an effective treatment for FD, but the effect appears 
to be limited to antipsychotics and tricyclic antidepressants with fewer trials for other agents, 
meaning that firm conclusions for efficacy cannot be made. More data from high quality 
RCTs are required to support their use in the treatment of FD.  
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What is already known about this subject? 
Functional dyspepsia (FD) is common and difficult to treat.  
Helicobacter pylori eradication therapy and proton pump inhibitors are efficacious treatments 
for FD, but the benefits are modest. 
Estimates of the efficacy of psychotropic drugs in FD have been hampered by a paucity of 
randomised controlled trials (RCTs), and a failure to report extractable dichotomous data.  
 
What are the new findings? 
We identified 13 RCTs, and successfully contacted original investigators to obtain 
supplementary dichotomous data.  
Psychotropic drugs were more effective than placebo for the treatment of FD, with a number 
needed to treat of 6 (95% confidence interval (CI) 4 to 16).  
However, this beneficial effect was limited to antipsychotic drugs, such as sulpiride and 
levosulpiride, and tricyclic antidepressants (TCADs), such as amitriptyline and imipramine. 
Adverse events were more common (number needed to harm 21 (95% CI 9 to 597)).   
 
How might it impact on clinical practice in the near future? 
Gastroenterologists should consider the use of some psychotropic drugs in FD, particularly 
TCADs.  
Our findings should stimulate further RCTs in this field. 
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INTRODUCTION 
 
Functional dyspepsia (FD) is a chronic disorder of the gastroduodenal region of the 
gastrointestinal (GI) tract. The condition is diagnosed using the Rome III criteria, which 
include the presence of epigastric pain or burning, early satiety during a normal-sized meal, 
or postprandial fullness, in the absence of an organic disease at upper GI endoscopy that 
would explain the symptoms. [1] The prevalence of FD in the community is between 5% and 
15% using these criteria, [2, 3] and the disorder follows a relapsing and remitting course. [4-
6] Functional dyspepsia has a significant impact on individuals, health services, and society, 
due to consultations with symptoms, [7] investigations, [8] medications, [9] and sickness-
related absences from work. [10] A recent burden of illness study estimated that FD costs the 
USA $18 billion per year, [11] and in the UK direct costs have been reported as being as high 
as £500 million, and indirect costs £1 billion, per year. [9] 
Effective management of the condition is therefore extremely important. 
Unfortunately, as the exact cause of FD remains obscure, there is no definitive therapy that is 
of benefit in all individuals. Patients with FD, as with most other functional GI disorders, 
exhibit higher levels of anxiety, depression, and other psychological conditions than healthy 
individuals. [2, 12] However, up to 80% of individuals report meal-induced symptoms, [13] 
and there is also evidence to suggest that delayed gastric emptying, [14] impaired fundal 
accommodation, [15] visceral hypersensitivity to painful stimuli, [16, 17] and abnormal 
central processing of pain, [18] are all implicated in the apparently heterogeneous 
pathophysiology of FD. In addition, recruitment of inflammatory cells, such as eosinophils, 
and altered mucosal integrity have also been demonstrated in patients with FD, [19, 20] and 
these types of changes may be associated with psychological stressors. [21]  
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Besides their pain modifying properties, [22, 23] and beneficial effects on mood, 
psychotropic drugs including tricyclic antidepressants (TCADs), selective serotonin re-uptake 
inhibitors (SSRIs), 5-hydroxytryptamine (5-HT)-1A receptor agonists, such as buspirone, and 
benzamides, such as levosulpiride, have all been shown to have effects on gastric motor 
function, which include increased gastric accommodation, enhanced pre-prandial gastric 
relaxation, and alterations in gastric emptying rate. [24-28] These effects on GI motility stem 
from their agonism or antagonism of receptors with an affinity for various neurotransmitters, 
including 5-HT receptors in the case of 5-HT1A agonists and SSRIs, the dopamine D2 
receptor in the case of benzamides, and 5-HT, dopamine D2, histamine, and acetylcholine 
receptors in the case of TCADs. As well as being located in the brain, these receptors are 
located throughout the GI tract. As a result, these drugs have been proposed as potential 
treatments for FD for many years, although national guidelines for the management of 
dyspepsia have highlighted that data to support their use are lacking. [29-31]  
In recent years, there have been several randomised controlled trials (RCTs) 
conducted that have assessed the efficacy of psychotropic drugs in FD, but some studies have 
been small, and the results have been conflicting. [32-34] In addition, physicians may be 
reluctant to consider using these drugs due to negative perceptions about their side-effect 
profile. Their role in the management of FD is therefore unclear at the present time. In an 
attempt to address this uncertainty, we have conducted a systematic review and meta-analysis 
of RCTs to estimate the efficacy and tolerability of psychotropic drug therapy in patients with 
FD. 
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METHODS 
 
Search Strategy and Study Selection 
 
A search of the medical literature was conducted using MEDLINE (1946 to 30th June 
2015), EMBASE and EMBASE Classic (1947 to 30th June 2015), PsychINFO (1806 to 30th 
June 2015), and the Cochrane central register of controlled trials. Randomised controlled 
trials examining the effect of psychotropic drugs in adult patients (over the age of 16 years) 
with FD were eligible for inclusion (Box 1). The first period of cross-over RCTs, prior to 
cross-over to the second treatment, were also eligible for inclusion. The control arms were 
required to receive placebo.  
Duration of therapy had to be at least 7 days. The diagnosis of FD could be based on 
either a physician’s opinion or symptom-based diagnostic criteria, with a negative upper GI 
endoscopy excluding an organic cause of dyspepsia. Subjects were required to be followed up 
for at least 1 week, and studies had to report a global assessment of FD symptom cure or 
improvement after completion of therapy, preferably as reported by the patient, but if this was 
not recorded then as documented by the investigator. Where studies did not report these types 
of data, but were otherwise eligible for inclusion in the systematic review, we attempted to 
contact the original investigators in order to obtain dichotomous data. 
Studies on FD were identified with the term dyspepsia (both as a medical subject 
heading (MeSH) and a free text term), and dyspep$, satiety, epigastric adj5 pain, upper 
gastrointestinal symptom$, or upper gastrointestinal adj5 symptoms (as free text terms). 
These were combined using the set operator AND with studies identified with the terms: 
antidepressive agents (second generation), antidepressive agents, antidepressive agents 
(tricyclic), psychotropic drugs, serotonin uptake inhibitors, sulpiride, mianserin, 
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desipramine, imipramine, trimipramine, doxepin, dothiepin, nortriptyline, amitriptyline, 
paroxetine, sertraline, fluoxetine, or citalopram (both as MeSH terms and free text terms), 
and the following free text terms: venlafaxine, duloxetine, escitalopram, levosulpiride, 
mirtazapine, tricyclic, desimipramine, buspirone, or tandospirone.  
There were no language restrictions and abstracts of the papers identified by the initial 
search were evaluated by two reviewers for appropriateness to the study question, and all 
potentially relevant papers were obtained and evaluated in detail. Foreign language papers 
were translated where necessary. Abstract books of conference proceedings from Digestive 
Diseases Week and United European Gastroenterology Week between 2001 and 2014 were 
hand-searched to identify potentially eligible studies published only in abstract form. The 
bibliographies of all identified relevant studies were used to perform a recursive search of the 
literature. Articles were assessed independently by two reviewers using pre-designed 
eligibility forms, according to the prospectively defined eligibility criteria. Any disagreement 
between investigators was resolved by consensus.  
 
Outcome Assessment 
 
The primary outcomes assessed were the effects of psychotropic drugs compared with 
placebo on global FD symptoms after cessation of therapy. Secondary outcomes included 
adverse events occurring as a result of therapy, and adverse events leading to study 
withdrawal. 
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Data Extraction 
 
All data were extracted independently by two reviewers on to a Microsoft Excel 
spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA) as dichotomous 
outcomes (global FD symptoms unimproved) (Box 2), with disagreements resolved by 
consensus. In addition, the following clinical data were extracted for each trial: setting 
(primary, secondary, or tertiary care-based), country of origin, dose and class of psychotropic 
drug administered, duration of therapy, total number of adverse events reported, total number 
of adverse events leading to withdrawal, criteria used to define FD, primary outcome measure 
used to define symptom improvement following therapy, and proportion of female patients. 
Data were extracted as intention-to-treat analyses, with all drop-outs assumed to be treatment 
failures, wherever trial reporting allowed this.  
 
Assessment of Risk of Bias 
 
This was performed independently by two investigators, with disagreements resolved 
by consensus. Risk of bias was assessed as described in the Cochrane handbook, [35] by 
recording the method used to generate the randomisation schedule and conceal allocation, 
whether blinding was implemented for participants, personnel and outcome assessment, what 
proportion of subjects completed follow-up, and whether there was evidence of selective 
reporting of outcomes. 
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Data Synthesis and Statistical Analysis 
 
Data were pooled using a random effects model, [36] to give a more conservative 
estimate of the effect of psychotropic drugs, allowing for any heterogeneity between studies. 
The impacts of different interventions were expressed as a relative risk (RR) of global FD 
symptoms not improving with psychotropic drugs compared with placebo, with 95% 
confidence intervals (CI). Adverse events data were also summarised with RRs. The number 
needed to treat (NNT) and the number needed to harm (NNH), with 95% CIs, were calculated 
using the formula NNT or NNH = 1 / (control event rate x (1 – RR)).  
Heterogeneity, which is variation between individual study results arising as a result 
of either differences in study participants or methodology, was assessed using both the I2 
statistic with a cut off of ≥50%, and the chi-squared test with a P value <0.10, used to define 
a significant degree of heterogeneity. [37] Where the degree of statistical heterogeneity was 
greater than this between trial results in this meta-analysis, possible explanations were 
investigated using subgroup analyses according to type of psychotropic drug used, trial 
setting, criteria used to define FD, whether individual trials screened for and excluded 
individuals with co-existent mood disorders, and risk of bias of included trials. These were 
exploratory analyses only, and may explain some of the observed variability, but the results 
should be interpreted with caution.   
Review Manager version 5.1.4 (RevMan for Windows 2008, the Nordic Cochrane 
Centre, Copenhagen, Denmark) and StatsDirect version 2.7.7 (StatsDirect Ltd, Sale, 
Cheshire, England) were used to generate Forest plots of pooled RRs for primary and 
secondary outcomes with 95% CIs, as well as funnel plots. The latter were assessed for 
evidence of asymmetry, and therefore possible publication bias or other small study effects, 
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using the Egger test, [38] if there were sufficient (10 or more) eligible studies included in the 
meta-analysis, in line with current recommendations. [39] 
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RESULTS 
 
The search strategy identified a total of 2795 citations, of which 34 published articles 
appeared to be relevant, and were retrieved for further assessment. Of these 34, 21 were 
excluded for various reasons leaving 13 eligible studies (Figure 1). [25, 27, 32, 33, 40-48] 
Agreement between reviewers for assessment of trial eligibility was good (kappa statistic = 
0.77). We successfully contacted original investigators to seek clarification on study 
methodology, and hence reduce risk of bias, or to obtain supplementary dichotomous data for 
nine trials. [25, 32, 33, 42-46, 48] Three trials used antipsychotic drugs, [27, 40, 41] three 
trials 5-HT1A receptor agonists, [25, 43, 44] two trials TCADs, [45, 46] one trial SSRIs, [32] 
one trial tetracyclic antidepressants, [48] one trial serotonin-norepinephrine re-uptake 
inhibitors (SNRIs), [33] one trial SSRIs or TCADs, [47] and one trial a combination of an 
antipsychotic drug and a TCAD. [42] Ten of the RCTs were at low risk of bias 
(Supplementary Table 1). [25, 32, 33, 42-48]  
The proportion of female patients recruited by trials ranged from 56.0% to 85.3%. Six 
trials screened for, and excluded, individuals with co-existent mood disorders. [25, 42, 44, 45, 
47, 48] In the trial by Braak et al. seven (10.3%) of 68 screening failures were due to a mood 
disorder. [45] Among the other studies, three reported reasons for screening failure and none 
were due to a mood disorder, [25, 42, 44] and two did not report these data. Detailed 
characteristics of individual RCTs are provided in Table 1.
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Table 1. Characteristics of Randomised Controlled Trials of Psychotropic Drugs Versus Placebo in Functional Dyspepsia. 
Study name 
and year 
Country Setting Diagnostic criteria 
used for FD 
Criteria used to 
define symptom 
improvement 
following therapy 
Sample 
size (% 
female) 
Psychotropic drug 
used and duration 
of therapy 
Screened 
for mood 
disorder 
prior to 
entry? 
Methodology 
Hui 1986 
[40] 
Hong Kong, 
China 
Tertiary 
care 
Clinical diagnosis 
and negative 
investigations 
Patient-reported 
improvement in, or 
resolution of, dyspeptic 
symptoms 
100 
(58.0) 
Sulpiride 100mg 
q.i.d*. for 1 week, 
then 50mg q.i.d. for 3 
weeks 
Yes, but not 
excluded 
Method of 
randomisation and 
concealment of 
allocation not stated. 
Double-blind. Antacids 
only allowed. 
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Arienti 1994 
[27] 
Italy Tertiary 
care 
Clinical diagnosis 
and negative 
investigations 
Patient-reported 
improvement in 
dyspeptic symptoms 
using a visual analogue 
scale 
30 (63.3) Levosulpiride 25mg 
t.i.d.† for 20 days 
No Method of 
randomisation and 
concealment of 
allocation not stated. 
Double-blind. No other 
FD medications 
allowed. 
Song 1998 
[41] 
South Korea Tertiary 
care 
Clinical diagnosis 
and negative 
investigations, 
delayed gastric 
empting present in 
all patients 
Patient-reported global 
efficacy of treatment 
rated as excellent or 
good 
42 (78.6) Levosulpiride 25mg 
t.i.d. for 3 weeks 
No Method of 
randomisation and 
concealment of 
allocation not stated. 
Double-blind. No other 
FD medications 
allowed. 
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Hashash 
2008 [42] 
Lebanon Tertiary 
care 
Rome III criteria and 
negative 
investigations 
Patient-reported 
subjective feeling of 
global symptom relief 
25 (56.0) Flupenthixol 0.5mg 
and melitracen 10mg 
b.i.d.‡ for 2 weeks 
Yes, no 
patients with 
anxiety 
recruited 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. Unclear 
if other FD 
medications allowed. 
van 
Kerkhoven 
2008 [33] 
The 
Netherlands 
Secondary 
care 
Clinical diagnosis 
and negative 
investigations 
Patient-reported 
absence of symptoms 
on a 7-point Likert 
scale 
160 
(59.4) 
Venlafaxine 75mg 
o.d.§ for 2 weeks, 
then 150mg o.d. for 4 
weeks, then 75mg 
o.d. for 2 weeks 
Yes, but not 
excluded 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. No other 
FD medications 
allowed. 
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Tack 2009 
[44] 
Belgium, 
Germany, and 
The 
Netherlands 
Tertiary 
care 
Rome II criteria and 
negative 
investigations 
30% improvement in 
patient assessment of 
upper GI symptom 
severity|| 
53 (66.0) R-137696 2mg t.i.d. 
for 4 weeks 
Yes, and 
excluded 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. No other 
FD medications 
allowed. 
Miwa 2009 
[43] 
Japan Secondary 
and tertiary 
care 
Rome II criteria and 
negative 
investigations 
Patient-reported total 
abdominal symptom 
score of 0 or 1 on a 
modified 
gastrointestinal 
symptom rating scale 
150 
(73.3) 
Tandospirone 10mg 
t.i.d. for 4 weeks 
Yes, but not 
excluded 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. No other 
FD medications 
allowed. 
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Braak 2011 
[45] 
The 
Netherlands 
Tertiary 
care 
Rome III criteria and 
negative 
investigations 
30% improvement in 
patient assessment of 
upper GI symptom 
severity|| 
38 (60.5) Amitriptyline 25mg 
o.d. for 8 weeks 
Yes, and 
excluded 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. No other 
FD medications 
allowed. 
Wu 2011 
[46] 
Hong Kong, 
China 
Tertiary 
care 
Rome II criteria and 
negative 
investigations 
Patient-reported relief 
of global symptoms 
107 
(80.4) 
Imipramine 25mg 
o.d. for 2 weeks, then 
50mg o.d. for 10 
weeks 
Yes, but not 
excluded 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. Other 
FD medications 
allowed. 
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Tack 2012 
[25] 
Belgium Tertiary 
care 
Rome II criteria and 
negative 
investigations 
30% improvement in 
patient-reported 
dyspepsia symptom 
severity|| 
17 (76.5) Buspirone 10mg t.i.d. 
for 4 weeks 
Yes, and 
excluded 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. No other 
FD medications 
allowed. 
Tan 2012 
[32] 
Hong Kong, 
China 
Tertiary 
care 
Rome II criteria and 
negative 
investigations 
Patient-reported relief 
of global symptoms 
193 
(72.0) 
Sertraline 50mg o.d. 
for 8 weeks 
Yes, but not 
excluded 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. Other 
FD medications 
allowed. 
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Tack 2015 
[48] 
Belgium Tertiary 
care 
Rome III criteria and 
negative 
investigations, 
weight loss present 
in all patients 
30% improvement in 
patient-reported 
dyspepsia symptom 
severity|| 
34 (85.3) Mirtazepine 15mg 
o.d. for 8 weeks 
Yes, and 
excluded 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. No other 
FD medications 
allowed. 
Talley 2015 
[47] 
USA and 
Canada 
Tertiary 
care 
Rome II criteria and 
negative 
investigations 
Patient-reported 
adequate relief of  
global symptoms for 
50% of weeks during 
weeks 3 to 12 
292 
(75.0) 
Amitriptyline 25mg 
o.d. for 2 weeks, then 
50mg o.d. for 10 
weeks, or 
escitalopram 10mg 
o.d. for 12 weeks 
Yes, and 
excluded 
Method of 
randomisation and 
concealment of 
allocation stated. 
Double-blind. Other 
FD medications 
allowed. 
 
*q.i.d.; four times daily 
† t.i.d.; thrice-daily  
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‡ b.i.d.; twice-daily 
§o.d.; once-daily 
||Dichotomous data obtained from original investigators 
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Efficacy of Psychotropic Drugs in the Treatment of FD 
 
In total, there were 1241 patients, 673 of whom received active therapy and 
568 placebo. Overall, 388 (57.7%) of 673 patients assigned to psychotropic drugs 
reported persistent or unimproved FD symptoms following therapy, compared with 
407 (71.7%) of 568 allocated to placebo. The RR of FD symptoms persisting or not 
improving after treatment with psychotropic drugs versus placebo was 0.78 (95% CI 
0.68 to 0.91), with significant heterogeneity detected between studies (I2 = 64%, P < 
0.001) (Figure 2). There was statistically significant asymmetry in the funnel plot 
(Egger test, P = 0.003), suggesting publication bias or other small study effects 
(Supplementary Figure 1). In view of this, we conducted a sensitivity analysis using a 
fixed effects model, but the results were almost identical (RR = 0.82; 95% CI 0.76 to 
0.89). The NNT with psychotropic drugs was 6 (95% CI 4 to 16).  
Subgroup analyses were conducted (Table 2). These revealed that the 
beneficial effect of psychotropic drugs appeared to be limited to antipsychotics and 
TCADs. In addition, a significant treatment effect was only seen in trials that were 
conducted in tertiary care, although these constituted the majority of studies. When 
only studies that screened for and excluded individuals with a co-existent mood 
disorder were considered in the analysis, there was no longer a significant effect of 
psychotropic drugs on FD. Importantly, when the analysis was limited to the 10 trials 
at low risk of bias, the beneficial effect of psychotropic drugs persisted. A summary 
of the quality of the evidence for the efficacy of psychotropic drugs, using GRADE 
criteria, [49] is provided in Supplementary Table 2. 
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Table 2. Subgroup Analyses of Randomised Controlled Trials of Psychotropic Drugs Versus Placebo in Functional Dyspepsia. 
 Number of 
trials 
Number of 
patients 
Relative risk of FD symptoms not improving 
(95% CI) 
NNT (95% CI) I2 
(P value) 
All studies 13 1241 0·78 (0·68 to 0·91) 6 (4 to 16) 64% (<0·001) 
Drug class used 
Antipsychotics 
TCADs 
5-HT1A receptor agonists 
SSRIs 
SNRIs 
Tetracyclic antidepressants 
Antipsychotics and TCADs 
 
3 
3 
3 
2 
1 
1 
1 
 
172 
339 
220 
388 
160 
34 
25 
 
0·50 (0·37 to 0·67) 
0·74 (0·61 to 0·91) 
0·85 (0·62 to 1·18) 
1·01 (0·89 to 1·15) 
1·02 (0·80 to 1·30) 
0·73 (0·50 to 1·08) 
0·31 (0·11 to 0·87) 
 
3 (2 to 4) 
6 (4 to 18) 
Not estimable 
Not estimable 
Not estimable 
Not estimable 
2 (1.5 to 10) 
 
0% (0·91) 
0% (0·73) 
65% (0·06) 
0% (0·91) 
Not applicable* 
Not applicable* 
Not applicable* 
Setting 
Tertiary care only  
Secondary and tertiary care 
 
11 
2 
 
931 
310 
 
0·74 (0·61 to 0·89) 
0·88 (0·68 to 1·15) 
 
6 (4 to 13) 
Not estimable 
 
68% (<0·001) 
68% (0·08) 
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Criteria used to define FD 
Rome II 
Clinical diagnosis 
Rome III 
 
6 
4 
3 
 
812 
332 
97 
 
0·89 (0·77 to 1·03) 
0·62 (0·38 to 1·00) 
0·67 (0·47 to 0·94) 
 
Not estimable 
Not estimable 
4 (2 to 20) 
 
54% (0·04) 
79% (0·003) 
28% (0·25) 
Screened for and excluded 
individuals with co-existent mood 
disorder 
Yes 
No 
 
 
 
6 
7 
 
 
 
459 
782 
 
 
 
0·83 (0·67 to 1·02) 
0·74 (0·59 to 0·93) 
 
 
 
Not estimable 
5 (3 to 20) 
 
 
 
52% (0·05) 
75% (<0·001) 
Risk of bias 
Low 
Unclear or high 
 
10 
3 
 
1069 
172 
 
0·86 (0·76 to 0·98) 
0·50 (0·37 to 0·67) 
 
10 (6 to 72) 
3 (2 to 4) 
 
51% (0·02) 
0% (0·96) 
*Too few studies to assess heterogeneity 
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Adverse Events with Psychotropic Drugs 
 
Data concerning total numbers of adverse events were available for 11 of the 
trials. [25, 27, 32, 40-45, 47, 48] For five studies, these were obtained by direct 
contact with the original investigators. [25, 32, 42, 44, 48] There were 118 (21.9%) of 
538 patients assigned to psychotropic drugs experiencing any adverse event, 
compared with 73 (16.7%) of 436 allocated to placebo. When data were pooled, the 
incidence of adverse events was significantly higher among those taking psychotropic 
drugs (RR of experiencing any adverse event = 1.28; 95% CI 1.01 to 1.63), with no 
heterogeneity between results I2 = 0%, P = 0.47) (Figure 3), and a NNH of 21 (95% 
CI 9 to 597). When type of psychotropic drug was studied, total adverse events were 
only significantly higher with TCADs in two trials (RR = 1.65; 95% CI 1.11 to 2.45), 
[45, 47] with a NNH of 7 (95% CI 3 to 40).  
Adverse events leading to withdrawal from each of the trials were available 
for all included studies. [25, 27, 32, 33, 40-48] For eight RCTs these were obtained by 
contacting involved investigators. [25, 33, 42-47] In total, 78 (11.6%) of 673 patients 
assigned to psychotropic drugs experienced adverse events leading to withdrawal, 
compared with 35 (6.2%) of 568 allocated to placebo. When data were pooled the 
incidence of adverse events leading to withdrawal was significantly higher among 
those taking psychotropic drugs (RR of experiencing adverse events leading to 
withdrawal = 1.76; 95% CI 1.22 to 2.55), again with no heterogeneity between results 
(I2 = 0%, P = 0.50) (Figure 4). The NNH was 21 (95% CI 10 to 74). Adverse events 
leading to withdrawal were significantly higher with SSRIs in two trials (RR = 1.94; 
95% CI 1.03 to 3.67, NNH = 16; 95% CI 6 to 492),[32, 47] and SNRIs in one trial 
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(RR = 4.25; 95% CI 1.50 to 12.07, NNH = 6; 95% CI 2 to 40), [33] but not with any 
other type of psychotropic drug.  
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DISCUSSION 
 
This systematic review and meta-analysis has demonstrated that psychotropic 
drugs appear to be an effective treatment for FD, with an NNT of six when data from 
all studies were pooled. However, this beneficial effect appeared to be limited to 
TCADs and antipsychotics, such as levosulpiride. There was no significant difference 
detected between SSRIs, SNRIs, tetracyclic antidepressants, or 5-HT1A receptor 
agonists and placebo. With two negative studies of SSRIs, containing almost 400 
patients, it would be reasonable to assume that these drugs are of no benefit in FD, but 
for other agents the total number of trials and included patients were fewer, and in the 
case of 5-HT1A receptor agonists it should be pointed out that the largest trial, which 
used tandospirone, demonstrated a significant benefit of this drug. Total numbers of 
adverse events, and adverse events leading to withdrawal, were significantly higher 
among those taking psychotropic drugs, with a NNH of 21 for both these endpoints.   
This systematic review and meta-analysis used rigorous methodology. We 
reported our search strategy, which included searching the “grey” literature, and 
assessment of eligibility and data extraction was performed independently by two 
reviewers. We used an intention-to-treat analysis and pooled data with a random 
effects model, to minimise the likelihood that treatment effect of psychotropic drugs 
in FD would be overestimated. We also contacted investigators of potentially eligible 
studies to either obtain supplementary dichotomous data for effect of treatment on 
symptoms and adverse events with therapy that were not reported in the original 
publications, or to clarify study methodology in order to minimise the risk of bias of 
included RCTs. This inclusive approach has provided us with access to data for >1200 
FD patients treated with psychotropic drugs versus placebo. In addition, we performed 
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subgroup analyses to explore reasons for heterogeneity between studies, and to assess 
treatment effect according to individual therapy used, study setting, criteria used to 
define FD, exclusion of patients with pre-existing mood disorder, and risk of bias of 
included studies. Finally, we extracted and pooled adverse events data, where 
reported, and again contacted the original investigators in order to maximise the data 
available for synthesis.  
There are limitations to this systematic review and meta-analysis, some of 
which arise from the nature of the studies available for synthesis. Three of the 
included trials were unclear risk of bias, [27, 40, 41] due to a lack of reporting of the 
methods used to generate the randomisation schedule and conceal allocation, which 
may lead to overestimation of the treatment effect. However, the difference in favour 
of psychotropic drugs remained statistically significant when only trials at low risk of 
bias were included in the analysis. The use of subjective, dichotomous outcomes in all 
the included trials, rather than mechanistic endpoints, may have led to a higher 
placebo response rate, similar to that seen in treatment trials in irritable bowel 
syndrome. [50] In addition, the fact that some studies included individuals with 
psychological co-morbidity may limit the generalisability of our findings to patients 
with FD outside of specialist referral centres. Finally, it should be pointed out that the 
longest duration of therapy in any of the RCTs we identified was 12 weeks, meaning 
that the longer term efficacy of psychotropic drugs in FD is unknown. 
In terms of limitations of the findings of the meta-analysis itself, there was 
evidence of heterogeneity between RCTs in our primary analysis, although not when 
TCADs or SSRIs were considered separately, or when only studies that used the 
Rome III criteria to define FD were included in the analysis. There was also evidence 
of publication bias, or other small study effects, when data from all trials were pooled. 
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If this were due to a genuine failure to publish small negative RCTs of psychotropic 
drugs in FD, this could mean that the observed treatment effect has been 
overestimated. We used NNTs and NNHs to summarise efficacy and safety, which are 
defined as the expected number of people who need to receive the experimental, 
rather than the comparator, intervention for one additional person to either incur or 
avoid an event in a given time frame. Their calculation was based on the pooled 
control event rate and RR. These are time dependent variables and may vary with 
durations of follow-up. [51] The follow-up duration of included studies in this review 
ranged from 2 weeks to 12 weeks, therefore, the NNT and NNH and their interval 
estimations should be interpreted as a range that can be expected within this time 
frame. 
Although proton pump inhibitors (PPIs) and Helicobacter pylori eradication 
therapy are efficacious treatments for FD, the benefits are modest, [52, 53] and a 
considerable proportion of patients therefore do not experience relief of their 
symptoms with either of these approaches. This, together with the fact that most 
prokinetics are either ineffective, [54] or have been withdrawn or are restricted due to 
concerns about their safety profile, [55] means that there is a large unmet need for 
effective therapies in FD. Previous attempts to summarise the literature concerning 
the role of psychotropic drugs in FD, and to estimate their efficacy, have been 
hampered by a paucity of trials, and a failure to report extractable dichotomous data, 
meaning that a formal meta-analysis has not been possible until now. [56, 57] As a 
result current national guidelines for the management of FD are equivocal concerning 
the role of psychotropic drugs in FD. [29-31]   
This underlines the importance of the current meta-analysis, which has 
highlighted that antipsychotic drugs and TCADs are more effective than placebo in 
Ford et al.   30 of 48 
FD patients in secondary or tertiary care. However, it remains uncertain whether other 
psychotropic drugs, including 5-HT1A receptor agonists, tetracyclic antidepressants, or 
SNRIs are effective treatments in FD. With respect to 5-HT1A receptor agonists, 
although there have been three trials, [25, 43, 44] each used a different drug, and the 
results were conflicting. In the case of tetracyclic antidepressants and SNRIs there has 
been only one trial of each of these drug classes. The trial of mirtazapine suggested a 
benefit of the drug in FD patients with weight loss (the inclusion criterion), but was 
relatively small and not powered for a dichotomous endpoint. [48] The RCT of 
venlafaxine was larger, [33] but has been criticised for its use of an agent with an 
adverse side-effect profile, leading to a high dropout rate, and the dosing regimen 
used, which included titration of the dose up to 150mg daily over the first 6 weeks, 
followed by a reduction to 75mg once daily during the last 2 weeks. [58] 
The mechanism of action for the beneficial effect of some psychotropic drugs 
in FD may arise from their effects on neurotransmitters in the brain, through their 
local actions in the GI tract, or both. TCADs target serotonergic neurotransmission, 
while antipsychotic agents are D2 receptor antagonists, among other actions. The 
intestinal enterochromaffin cells contain 90% of the body’s total stores of 5-HT, [59, 
60] which is integral to GI motility. Antagonism of D2 receptors in the myenteric 
plexus promotes gastric emptying, pyloric relaxation, and increased lower 
oesophageal sphincter tone, [61] which may explain the beneficial effects of 
benzamides such as sulpiride and levosulpiride, and suggests that the efficacy of drugs 
with a better side-effect profile but with a similar mechanism of action should be 
explored in FD. Finally, central inhibitory effects of TCADs on 5-HT and 
norepinephrine re-uptake may lead to their visceral analgesic properties, while their 
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anticholinergic effects may alter GI motility, [62] although this was not observed with 
low-dose amitriptyline. [47]  
Whether these drugs are effective in patients with FD in primary care, and also 
whether they are more effective than established drugs, such as PPIs, for the treatment 
of the condition cannot be determined from this meta-analysis. There is also 
uncertainty as to whether some of the benefit of psychotropic drugs in FD arises from 
the treatment of co-existent mood disorder, with a larger treatment effect observed in 
studies that did not exclude patients with co-existent mood disorder. For SSRIs, this 
theory is plausible, as the doses used in the two trials were close to those used to treat 
depression, but this would seem less likely for TCADs, where the doses used were 
considerably lower than the therapeutic range considered as effective for the treatment 
of mood disorders. The efficacy of these therapies according to FD subtype (epigastric 
pain syndrome or post-prandial distress syndrome) has not been well-studied. Future 
trials should be undertaken in primary care, and could stratify patients according to 
presence or absence of co-existent mood disorder, and FD subtype, in order to explore 
these unresolved questions. Finally, the long-term side-effects of TCADs were not 
able to be considered, although there may be risks. [63] 
In summary, this systematic review and meta-analysis has demonstrated that, 
overall, psychotropic drugs are more effective than placebo for the treatment of FD. 
However, this beneficial effect was limited to antipsychotic drugs, such as sulpiride 
and levosulpiride, and TCADs, such as amitriptyline and imipramine. This has 
implications for the management of a condition that clinicians often find challenging, 
and should encourage appropriate use of these agents by gastroenterologists, and 
stimulate further RCTs in this field.
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Box 1. Eligibility criteria. 
 
Randomised controlled trials  
Adults (participants aged > 16 years)  
Diagnosis of functional dyspepsia based on either a clinician’s opinion, or meeting 
specific diagnostic criteria*, supplemented by negative endoscopy. 
Compared psychotropic drugs with placebo.  
Minimum duration of therapy 7 days. 
Minimum duration of follow-up 7 days. 
Dichotomous assessment of response to therapy in terms of effect on global functional 
dyspepsia symptoms following therapy at study end.†  
 
*Rome I, II, or III criteria. 
†Preferably patient-reported, but if this was not available then as assessed by a 
physician. 
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Box 2. Data extraction methodology. 
 
Outcome of interest: improvement in global functional dyspepsia symptoms. 
Reporting of outcomes: patient-reported preferable, if not available then 
investigator-reported. 
Time of assessment: at last point of follow-up whilst still on therapy. 
Denominator used: true intention-to-treat analysis, if not available then all evaluable 
patients.  
Cut off used for dichotomisation: any improvement in global functional dyspepsia 
symptoms or abdominal pain for Likert-type scales, investigator-defined improvement 
for continuous scales.  
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FIGURE LEGENDS 
 
Figure 1. Flow Diagram of Assessment of Studies Identified in the Systematic 
Review and Meta-analysis.  
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Figure 2. Forest Plot of Efficacy of Psychotropic Drugs Versus Placebo in 
Randomised Controlled Trials in Functional Dyspepsia. 
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Figure 3. Forest Plot of Adverse Events with Psychotropic Drugs Versus Placebo 
in Randomised Controlled Trials in Functional Dyspepsia. 
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Figure 4. Forest Plot of Adverse Events Leading to Withdrawal with 
Psychotropic Drugs Versus Placebo in Randomised Controlled Trials in 
Functional Dyspepsia. 
 
 
